A historic first.

The Swiss laboratory Novartis has signed a license agreement to facilitate access to a treatment against chronic myeloid leukemia;

the Medicines Patent Pool (MPP) organization said on Thursday.

This is the first such agreement for a cancer drug.

Through this agreement, selected generic drug manufacturers will be able to develop, manufacture and market generic versions of nilotinib in the territory covered by the voluntary license;

said in a press release the MPP, an international organization supported by the United Nations and based in Geneva.


#BREAKING｜🤝🏽@MedsPatentPool signs a license agreement with @Novartis to increase access to #nilotinib for the treatment of chronic myeloid #leukaemia.



Access our #PressRelease👉🏽 https://t.co/h7lP7kHP13@ATOM_Coalition #HealthForAll #Access2Meds #PublicHealth #cancer #WCC2022 pic.twitter.com/YqWd4RBlYb

— MedicinesPatentPool (@MedsPatentPool) October 20, 2022

Access to this content has been blocked to respect your choice of consent

By clicking on "

I ACCEPT

", you accept the deposit of cookies by external services and will thus have access to the content of our partners

I ACCEPT

And to better remunerate 20 Minutes, do not hesitate to accept all cookies, even for one day only, via our "I accept for today" button in the banner below.

More information on the Cookie Management Policy page.


"Many other agreements" hoped for by the WHO

The territory covered notably includes seven middle-income countries: Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines and Tunisia, where patents on nilotinib are pending or in force.

“Access to quality medicines is a crucial component of the global response to the scourge of cancer”;

MPP executive director Charles Gore said in the statement.

“Even though the patent is soon to expire, this voluntary license in the area of ​​non-communicable diseases sets an important precedent that I hope will be replicated by other companies,” he asked.

This licensing agreement is the first MPP has entered into for a cancer treatment, and it is also the first time that a company has licensed a patented cancer drug through a public health-oriented voluntary licensing mechanism. .

"We are proud to be the first to enter into this new licensing agreement model with MPP," said Novartis President, Global Health and Sustainability, Lutz Hegemann.




Nilotinib is a twice-daily oral medication on the World Health Organization (WHO) Model List of Essential Medicines for the treatment of chronic myeloid leukemia (CML) in adults and children over 18 years of age. 'a year.

The WHO also welcomed the signing of this first license agreement on a cancer drug.

"We hope that it will mark a paradigm shift, and that many more licensing agreements for key patented anti-cancer drugs will be signed, so that patients around the world can benefit from them", affirmed the secretary of the Committee of WHO experts for the selection and use of essential drugs, Benedikt Huttner.

Health

Pink October: "Life does not stop at 25", says Amandine, affected by breast cancer

Health

Carrefour: Recall of rice cakes potentially contaminated with a carcinogenic substance

  • Cancer

  • Leukemia

  • Treatment

  • Swiss

  • Health